BREATHOX
Commercial- Indications
- Muco-obstruction, Respiratory infections
Company intelligence / Profile preview
LIITA Care has developed BREATHOX®, a CE-marked medical device delivering inhalable dry sodium chloride particles to treat muco-obstructive respiratory conditions. A Phase 2 clinical trial demonstrated its use in reducing acute symptoms of COVID‑19 and potentially decreasing healthcare resource utilization. The OSMOVIR® platform is being positioned as a broad-spectrum antiviral approach targeting viral replication through induced hyper-osmosis rather than direct viral protein inhibition. Commercialization is ongoing in Northern Europe, with plans for expansion and additional partnerships underway.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LIITA Care.